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ABSTRACT 28 
OBJECTIVE: International guidelines recommend intra-articular steroid injections (IASI) in the 29 
management of hip osteoarthritis (OA), though these recommendations are extrapolated primarily 30 
from studies of knee OA. The aim of this systematic review was to assess the efficacy of IASI on 31 
pain in hip OA. 32 
METHODS: MEDLINE, EMBASE, AMED, CINAHL Plus, Web of Science and the Cochrane Central 33 
Register of Controlled Trials were searched to May 2015. RCTs assessing the efficacy of hip IASI 34 
on pain were included. Pre-specified data was extracted using a standardised form. Quality was 35 
assessed  using the Jadad score.  36 
RESULTS Five trials met the inclusion criteria. All had a small number of participants (≤101). All 37 
studies reported some reduction in pain at 3-4 weeks post-injection compared to control. Based on 38 
data from individual trials the treatment effect size was large at 1 week post-injection but declined 39 
thereafter.  A significant (moderate effect size) reduction in pain was reported in 2 trials up to 8 40 
weeks following IASI. Pooled results of 2 trials (N=90) showed an increased likelihood of meeting 41 
the OMERACT-OARSI response criteria at 8 weeks post-IASI, odds ratio 7.8 (95% CI 2.7-22.8). The 42 
number needed to treat to achieve one OMERACT-OARSI responder at 8 weeks post-injection was 43 
2.4 (95% CI 1.7-4.2). Hip IASI appear to be generally well tolerated. 44 
CONCLUSIONS: Hip IASI may be efficacious in short term pain reduction in those with hip OA 45 
though the quality of the evidence was relatively poor. Further large, methodologically rigorous trials 46 
are required to verify whether intra-articular corticosteroids are beneficial and for how long.  47 
 48 
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To date there are no effective therapies which reduce disease progression in hip OA and 55 
management is primarily focused on optimum pain control and maintaining function. There are, 56 
however, limitations with current analgesic therapies.  Oral analgesic therapy is restricted by 57 
duration, degree of efficacy and considerable associated toxicities.[1] Non-steroidal anti-58 
inflammatory drugs are associated with significant morbidity and mortality,[2] exacerbated by the co-59 
morbidities that are frequent in a typical OA population, whilst other analgesic medications, for 60 
example codeine, can cause nausea, constipation and drowsiness.[3]   61 
 62 
Intra-articular steroid therapy offers a potentially useful therapy as it is directly targeted at the 63 
affected joint with few systemic effects. Current guidelines produced by European League Against 64 
Rheumatism (EULAR),[4] the American College of Rheumatology (ACR)[5] and Osteoarthritis 65 
Research Society International (OARSI)[6] also recommend their use in the management of hip OA.  66 
However, as acknowledged by the ACR expert panel ‘few trials have been performed in patients 67 
with symptomatic hip OA,’ and their recommendations are based on their assessment that ‘patients 68 
with hip OA should be treated in a similar fashion to those with knee OA.’[5] A previous narrative 69 
review in 2008 concluded that, although there was a lack of evidence of efficacy and safety of IASI 70 
in hip OA, there was some evidence of short-term pain relief.[7] To date there have been no 71 
systematic reviews of the impact of IASI in the management of hip OA.  72 
The objective of this systematic review was to assess the efficacy of IASI in reducing pain in 73 
patients with hip OA. A secondary objective was to assess the effects of hip IASI on function and 74 

















Literature search 79 
MEDLINE, EMBASE, AMED, CINAHL Plus, Web of Science and the Cochrane Central Register of 80 
Controlled Trials were searched from inception to May 2015. No restrictions on language or date 81 
were applied. Search terms included synonyms of hip osteoarthritis, intra-articular injection, injection 82 
and steroids and common steroids used in intra-articular injections (methylprednisolone, 83 
triamcinolone and betamethasone) and associated brand names. Each database was searched 84 
individually with the search strategy optimised based on indexing method. Search terms were 85 
searched for both as free text and using terms indexed in each databases thesaurus (i.e. MeSH) 86 
where applicable. Full details of the MEDLINE search strategy appear in the supplementary data, 87 
available at Rheumatology online. To maximise the sensitivity of the search strategy no randomised 88 
controlled trial (RCT) or language filter was applied. Reference lists of relevant articles, reviews and 89 
clinical guidelines were also hand searched. To identify relevant unpublished trials the WHO Trial 90 
Search Portal and UK Clinical Trials Gateway were also searched. Eligibility assessment of trials for 91 
inclusion in the review was performed unblinded by 1 reviewer (P.S.M.) using a standardised form. 92 
 93 
Study selection 94 
This review included RCTs that assessed the use of hip IASI, using any steroid preparation, in 95 
patients with painful hip OA. The diagnosis of hip OA must have been based on the presence of hip 96 
pain and radiological evidence of OA. All trials must have included an intervention group which 97 
received a hip IASI and a control group who received a placebo (sham injection, normal saline or 98 
local anaesthetic intra-articular injection). Trials comparing IASI with another active treatment 99 
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Outcome measures 102 
The a priori outcome of interest was self-reported pain. Data was extracted for all reported pain 103 
measures and for the secondary outcome of function. Previous reports suggest that IASI in the knee 104 
have a significant, but relatively short lived effect on pain and may also have transient effects on 105 
function[8] and therefore we extracted pain and function outcome data at all reported time points.  106 
 107 
Quality Assessment 108 
The quality of included trials was independently assessed by reviewers (P.S.M and N.M.) using the 109 
scoring system suggested by Jadad et al,[9] a widely used and validated quality assessment tool for 110 
RCTs which includes assessment of blinding, randomisation and reporting of withdrawals and drop 111 
outs.[9, 10] In the event of disagreement the reviewers discussed their assessment to reach a 112 
consensus. 113 
 114 
Data Extraction 115 
Two authors (P.S.M and N.M.) independently extracted data from all studies utilising a standardised 116 
proforma. 117 
 118 
Quantitative Synthesis 119 
A quantitative synthesis of the OMERACT-OARSI response status at 8 weeks post-injection 120 
incorporating the results of 2 studies was performed. Analysis was undertaken in Review Manager 121 
version 5.3 (The Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen) utilising a 122 
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We also performed a further analysis, which considered the pain outcomes reported in the included 126 
studies. We took data from the highest ‘rated’ pain outcome available from each of the included 127 
trials, according to the hierarchy described by Jüni et al.[1] at the longest available reported follow-128 
up visit. Given the likelihood of high heterogeneity between trials with different follow-up lengths, 129 
and pain outcomes, we opted to use a random-effects Mantel-Haenszel model for this analysis, 130 
since it is more robust to heterogeneity in effects. Standardised mean differences were constructed, 131 
comparing the mean change in each pain outcome, between the active and control groups featured 132 
in each trial. Where within-person standard deviations in pain outcome were not reported, we 133 
contacted authors to obtain the unreported data. Where a response was not available, we imputed 134 
the mean difference standard deviations (SDbaseline-follow-up) by combining the standard deviations 135 
reported at baseline and follow up, with an estimated correlation between baseline and follow up 136 
visits of 0.5, and sensitivity analyses using correlations of 0.25 and 0.75, as per Cochrane 137 
Collaboration recommendations, [11] using the following formula: 138 
SDbaseline-follow-up=SDbaseline2  + SDfollow-up2 -(2 ×Corbaseline,follow-up)×SDbaseline ×SDfollow-up) 
 139 
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RESULTS 141 
Search results 142 
The search of literature databases identified 488 records potentially relevant to the study question 143 
(Figure 1). After removal of duplicates, 362 records remained and screening of the record title or 144 
abstract allowed exclusion of 324. For the remaining 36 records the full text article was read with 5 145 
studies meeting the inclusion criteria.[12-16] The reasons for exclusion included lack of 146 
randomisation,[17] no placebo control group,[18] clinical guideline only,[5-7] review article,[19-32] 147 
injection methods article or review,[33-36] trial protocol only[37] and others.[38-45]  148 
A search of trial registries identified one unpublished trial (clinical trials registration number 149 
NCT01079455) which was potentially relevant to this review. A published protocol for the trial was 150 
identified[37] and if performed per protocol would have met the review inclusion criteria. However, 151 
no published results were identified and the corresponding author did not respond to a request for 152 
further information. 153 
 154 
Characteristics of included studies  155 
A summary of the characteristics of included trials is shown in Table 1. Across all 5 included trials 156 
346 participants were randomised and 134 received a hip IASI. All trials were of a parallel design. 157 
The hip OA populations studied included those awaiting or eligible for a total hip arthroplasty 158 
(THA),[13,14,16] those refractory to simple analgesia [12] or any person meeting the ACR criteria 159 
for OA of the hip.[15] Three different steroid preparations (methylprednsiolone acetate[13,15] 160 
triamcinolone acetonide[16] and triamcinolone hexacetonide[12] were utilised and all studies used a 161 
different dose as shown in Table 1. One study did not report which triamcinolone salt was 162 
utilised.[14] All intra-articular injections were performed under image guidance either by 163 
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All studies had patient-reported pain as a primary outcome and 4 also included some assessment of 165 
function.[12,13,15,16]. A variety of different outcome measures were employed to assess pain 166 
including: numerical rating scale (NRS) of pain in general,[14] NRS worst pain,[13] visual analogue 167 
scale (VAS) of pain on weight bearing/walking and at rest,[15,16] and the Western Ontario and 168 
McMaster Universities osteoarthritis index (WOMAC) pain subscale.[12] Objective functional 169 
assessment included passive hip range of motion (ROM) [12.16]and subjective functional 170 
assessments: modified Katz ADL index,[16] SF-36 physical and social function score[12] and 171 
subjective algo-functional assessments (Lequesne index[15] and WOMAC global score[13,15]). 172 
Additional outcome measures included the Osteoarthritis Research Society International and 173 
Outcome measures in Rheumatology Clinical Trials (OARSI/OMERACT) response criteria[13,16] 174 
and patient global assessment.[13,15] All studies reported follow up durations of at least 8 weeks.  175 
 176 
Quality Assessment 177 
The quality of included trials was assessed using the Jadad scoring system and results are shown 178 
in Table 2. All studies scored 3 or more indicating high quality study design. Four studies were 179 
described as double blind [12,14-16] and one as single blind.[13] The inclusion of a single blind trial 180 
is unlikely to have introduced significant bias as the patients were blinded to treatment allocation 181 
and the trial only considered self-reported outcome measures.[13]  182 
Flanagan et al 1988,[14] prioritised participants for THA if they reported being worse at any follow 183 
up time point after intra-articular injection and were also censored from further participation in the 184 
trial. As the participants were aware of this from the outset there may have been an incentive to 185 
report being worse after the injection, however the study was double blind and therefore it was 186 
unlikely to have significantly affected the between group comparison.  In this study after 1 month 187 
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bupivacaine control group rendering it impossible to compare results between groups. The results 189 
beyond 1 month have therefore not been considered in this review. 190 
In Kullenberg et al 2004,[16] a double blind trial, the entire control group (n=40) withdrew after the 3 191 
weeks follow up which the authors report was due to inefficacy and thus there was no control group 192 
at 12 weeks, the primary end point. Only the results up to the 3 weeks post-injection have been 193 
included in the review. 194 
 195 
Effect on Pain 196 
A summary of the effect on pain for individual trials is shown in Figure 2. All trials reported some 197 
reduction in pain 3-4 weeks post hip IASI compared to controls across a diverse range of pain 198 
outcome measures.  Outcome beyond 4 weeks follow up was assessed in 3 trials.[12,13,15] Two 199 
trials included follow up at 8 weeks post-injection, and both reported clinically significant reductions 200 
in pain in the hip IASI group, compared to control, in either NRS of worst pain and/or WOMAC pain 201 
subscale.[12,13] At 8 weeks, across both trials, 29 of the 50 participants who received a hip IASI 202 
met the OMERACT-OARSI response criteria compared to only 6 out of 40 who received a control 203 
injection. As shown, Figure 3, a fixed-effects Mantel-Haenszel estimate of this effect gives an odds 204 
ratio of 7.8 (95% CI 2.7-22.4), favouring IASI. The risk difference for this odds ratio was 0.41 (95% 205 
CI 0.24-0.58) giving a number needed to treat to achieve 1 OMERACT-OARSI responder at 8 206 
weeks post-injection of 2.4 (95% CI 1.7-4.2).  207 
Only one trial, Qvistgaard et al[15] reported the results beyond 8 weeks. They reported a  208 
statistically significant reduction in pain in walking in the IASI group averaged across all follow up 209 
time points (2, 4 and 12 weeks), with an overall moderate effect size (standardised mean difference, 210 
SMD) of 0.6 (95% CI: 0.1-1.1). However, the difference between steroid and placebo groups in pain 211 
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weeks=0.006, P12 weeks=0.58). In contrast to Kullenberg et al[16] no significant reduction in pain at rest 213 
was reported at 3 weeks.    214 
 215 
The magnitude of pain reduction following hip IASI appears to be initially large but deceases over 216 
time. Atchia et al[13] reported an SMD of 1.5 and 1.9 for NRS worst pain and WOMAC pain 217 
subscale respectively 1 week post-injection. However by 4 weeks this had decreased to 1.0 and 1.1 218 
and at 8 weeks post-injection to 0.5 and 0.6 for NRS worst pain and WOMAC pain subscale 219 
respectively. Although the results reported by Lambert et al[12] suggest a less marked decrease in 220 
efficacy between 4 and 8 weeks, in keeping with all trials included in this review, insufficient data 221 
was available in the original publication to allow calculation of treatment effect size. The 222 
corresponding authors for the three published papers in the last 10 years[13,14,16]  were contacted 223 
to request additional information, or anonymised raw patient data, however, no additional 224 
information was obtained. Given the limited degree of available data, it was not possible to combine 225 
trial data in a formal meta-analysis (other than the limited fixed-effects odds-ratio estimate of 226 
OMERACT-OARSI responders, using the 8 weeks time point from two of the included studies). 227 
 228 
Figure 3 depicts a forest plot summarising the overall effect for the three trials which reported data 229 
on change in pain outcomes measured on a continuous scale. Overall, the observed degree of 230 
heterogeneity in effects in these trials was very high (I2 = 97%, p<0.001). The pooled overall SMD 231 
from these three trials was generally in favour of hip IASI, however this difference was not deemed 232 
statistically significant at the 0.05 level (SMD = -1.90; 95% CI -4.07 to 0.26; p = 0.08). Data from 233 
Atchia et al[13] did not report the required information to allow inclusion in this analysis, and imputed 234 
standard deviations were generated for the Lambert and Kullenberg et al trials[12,16[. Kullenberg et 235 
al reported data at follow up at both 3 weeks and 12 weeks, however the entire control group 236 
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analyses for this reason. Sensitivity analyses found that the overall treatment effect seen in figure 4 238 
varied greatly with the use of different estimated correlations between baseline and follow-up mean 239 
change in pain scores, This is perhaps unsurprising, given firstly that only three studies were able to 240 
be included in this analysis, and secondly since two thirds of the included studies had imputed data 241 
(and therefore were subject to change in the sensitivity analyses). 242 
 243 
Effect on function 244 
The secondary outcome of interest was effect of hip IASI on function. Of the 4 studies to assess 245 
function using subjective outcome measures 3 noted a statistically significant improvement in 246 
function in the steroid group compared to control.[12,13,15] These included a significant 247 
improvement in modified Katz ADL index at 3 weeks post injection,[16] WOMAC function subscale 248 
score[12,13] and SF-36 physical and social functioning subscales[12] at 8 weeks post-injection. 249 
Atchia et al[13] reported the magnitude and duration of the effect of hip IASI on WOMAC function 250 
subscale largely mirrored the effect on pain. At 1 week post-injection the SMD was large at 1.3, 251 
decreasing to 0.9 at 4 weeks, and 0.4 at 8 weeks with less marked reduction in efficacy reported by 252 
Lambert et al.[12] Two trials assessed hip ROM as an objective measure of hip function although 253 
the results were inconsistent. In one trial a very large and statistically significant increase in hip 254 
ROM was present at 3 weeks post hip IASI[16]; however, the only other study to assess ROM did 255 
not identify any significant difference at either 4 or 8 weeks post-injection.[12] 256 
 257 
Safety of hip IASI 258 
Four trials reported safety data.[12.13,15,16] Only one serious adverse event, a deep venous 259 
thrombosis 3 months post-injection, was reported in the IASI group.[12] The injection procedure 260 
itself was noted to be well tolerated.[12,13,15,16]  No adverse events in the IASI group were 261 
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group vs. 51% in the IASI group), and noted that ‘most were mild and/or considered unrelated to 263 
treatment.’[12] Qvistgaard et al noted that 3 patients (out of a total sample of 101) experienced a 264 
flare in pain post-injection but did not allocate these to a specific treatment group.[15]  265 
 266 
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DISCUSSION 268 
The evidence from this review suggests that hip IASI may be  efficacious in delivering short term, 269 
but clinically significant, pain reduction in those with hip OA, and may also lead to transient 270 
improvement in function. The treatment effect appears to be of rapid onset with a large treatment 271 
effect size reported at 1 week post-injection. The magnitude of pain reduction and functional 272 
improvement decreases thereafter, although two trials report clinically significant differences in both 273 
pain and function at 8 weeks post-injection.[12,13] This pattern is similar to that observed in studies 274 
of IASI at other sites in OA, such as the knee.[8]  275 
Because each trial used a different preparation or dose of steroid it was not possible to determine 276 
the effect of any particular dose on outcome. The injection procedure itself was well tolerated by trial 277 
participants[12,13,15,16] and only 1 serious adverse event in those receiving an IASI was 278 
reported.[12]  279 
This is the first systematic review to address the effect of hip IASI on pain and function. It utilised a 280 
broad and systematic search strategy to identify all the available evidence. There were nonetheless 281 
some limitations which need to be considered. As noted by the ACR guidelines expert panel, the 282 
number of studies performed in those with symptomatic hip OA is very small[5] and the review’s 283 
conclusions are based on the results of 5 trials containing only 346 participants in total. Small trials 284 
are recognised to potentially over-estimate treatment effect sizes,[46] or report a significant effect 285 
when none is present.[47] Thus a degree of caution is required in interpreting the results and it is 286 
not possible to draw firm conclusion on the efficacy of IASI in hip OA. The lack of available data 287 
made it difficult to undertake any formal assessment of this potential bias on treatment effect. All of 288 
the included trials were also of short duration and it remains unclear for how long hip IASI exert a 289 
clinically meaningful effect.  Additionally, the majority of participants were awaiting, or eligible for, a 290 
THA, which suggests that these participants had severe OA and so caution is needed in 291 
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The trial populations, consisting predominantly of those with severe hip OA, and the availability of 294 
an alternative effective treatment (THA) for this group, resulted in challenges in the conduct of the 295 
included trials. These included difficulties in recruitment leading to trials being stopped prior to 296 
recruiting the pre-specified sample size,[12] withdrawal of all controls prior to the primary end point 297 
due to inefficacy of the control treatment[16] and reduction in follow up duration due to participants 298 
undergoing THA[13] potentially increasing the risk of bias. We also cannot exclude publication bias 299 
in which trials that failed to show a treatment effect for IASI may have been less likely to have been 300 
published. Although we did search clinical trial registers and found only one, potentially ongoing, 301 
unpublished trial suggesting there is unlikely to be significant recent publication bias, we cannot 302 
exclude publication bias pre-dating the requirement for clinical trial registration.   303 
 304 
A large number of different pain and function outcome measures were utilised across the included 305 
trials. This significant heterogeneity in methodology between trials, coupled with the limited reporting 306 
of trial statistics, particularly for individual time points, limited the pooling of results into treatment 307 
effect sizes (standardised mean difference), in turn rendering it difficult to compare results between 308 
trials other than the limited fixed-effects odds-ratio estimate of OMERACT-OARSI responders, using 309 
the 8 week time point from two of the included trials and for an overall SMD in only three trials.. This 310 
highlights the importance of developing and use of core outcomes for clinical trials in this area. 311 
This review only included RCTs which incorporated a placebo group and thus did not consider trials 312 
comparing different doses of steroid or those comparing steroids with other treatments such as 313 
hyaluronic acid (HA) preparations. Whilst this did reduce the number of included trials, placebo 314 
effects are expected to be large in trials of injections in osteoarthritis, and this (large) effect would 315 
confound any observed treatment effect, making results less clear than in the present review.[48] 316 
Additionally, there is a lack of evidence on the efficacy of HA compared to placebo in the hip[49] and 317 
studies of HA in the knee suggest there are marked variations in treatment effect size for different 318 
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This review, is consistent with the recent Cochrane review of IASI in knee OA with regards the 320 
overall quality of the evidence, heterogeneity between trials and evidence of small study effects[8] 321 
and highlights the need for further research to confirm both the efficacy and the short and long term 322 
safety in IASI in the management of hip OA. Future trials should be sufficiently large and include a 323 
placebo group. Standardised outcomes such as those such as those recommended by OARSI[51] 324 
should be used and the results should be presented in a manner which will facilitate inclusion in 325 
future meta-analyses.  326 
 327 
In conclusion, hip IASIs, when performed with image guidance appear to be well tolerated and may 328 
be effective in reducing pain and improving function in the short term in those with severe hip OA, 329 
though the quality of the evidence is relatively poor. Further large, methodologically rigorous trials 330 
are required to verify whether intra-articular corticosteroids are beneficial and for how long. 331 
 332 
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et al 1988 
[14] 
Essex, UK 35 [12] range 
46-79 
Awaiting THR for OA Charnley  20mg Triamcinolone† + 0.5% 
Bupivicaine  
Fluoroscopy 4, 8, 12, 
26 
NRS 1-5 Not stated 
    0.5% Bupivicaine  
     Saline  
Kullenberg 




80 [40] 70 Awaiting THR Ahlbäck  80mg TA Fluoroscopy 3, 12 VAS - pain on 
weight bearing 
Not stated 
  Ahlback criteria ≥2 and 
JSN with cartilage 
destruction ≥ 50% 
1% Mepivacaine 
      Pain at rest and on 
weight bearing ≥ 3 VAS   
  
Qvistgaard 




101 [32] 66 Pain at randomisation ACR 40mg MP + 2 sham injections  Ultrasound 2, 4, 12 VAS-pain on 
walking 
Oak Foundation, Erna 
Hamilton Foundation and  
Fidia Inc.   Stable medication for 3 
week 
 3x Hyalgan   
      3x Saline    
            Injection repeated at 14 day 
intervals 
        
Lambert 




52 [31] 62 Symptoms for ≥ 6 
months 
ACR 40mg TH + 0.5% Bupivcaine Fluoroscopy 4, 8 WOMAC20 CHAR/NycoMed, MSI 
foundation, Arthritis 
Society of Canada, 
University of Alberta 
Foundation 
   Persistent pain despite 
paracetamol±NSAIDs 
0.5% Bupivicaine + Saline   






77 [19] 69 Unilateral hip OA ACR 120mg MP + 1% Lidocaine Ultrasound 1, 4, 8 NRS worst pain National institute of 
Health Research and 
National Health Service   
Pain >1 month 
 Durolane + 1% Lidocaine    
    
Listed for THR or NZ 
priority score ≥20  
 
Normal saline + 1% Lidocaine 
   
          Standard care - no injection         
* Where no primary pain outcome was specified the highest ranked pain measures reported in the hierarchy suggested by Juni et al [1]was utilised.  † Triamcinolone salt not specified.  
Abbreviation:  IASI – intra-articular steroid injection, MP – Methylprednisolone Acetate, NRS - Numerical rating scale, OARSI-Osteoarthritis research society international, THR - total hip replacement, TA - 
Triamcinolone Acetonide,  TH - Triamcinolone Hexacetonide, MP – Methylprednisolone ?acetate,  NSAIDs – Non-steroidal anti-inflammatory drugs, JSN – joint space narrowing,  ACR – American College of 































and drop outs 
Total Jadad 
Score 
Flanagan et al 1988 
[14] 
Yes Not reported Yes Yes No 3 
Kullenberg et al 2004 
[16] 
Yes Yes Yes Yes No 4 
Qvistgaard et al 2006 
[15] 
Yes Not reported Yes Yes Yes 4 
Lambert et al 2007 
[12] 
Yes Yes Yes Yes Yes 5 




































FIGURE 2.   











































































































































































































































































Flanagan et al 1988*                   
 
 9/12 in steroid group vs. 14/24 
control reported pain improved at 4 
weeks. No statistics reported. 
                       
Kullenberg et al 2004†                    Steroid group VAS pain on walking 
and at rest reported to be significantly 
different to control at 3 weeks. No p 
value reported. 
                       
Qvistgard et al 2006                     Pain on walking steroid group effect 
size 0.6 (95% CI:0.1-1.1) across all 
time points. Difference between 
placebo and steroid P4 weeks=0.006 P12 
weeks=0.58. 
                       
Lambert et al 2007                    OARSI responder criteria: 22/31 in the 
steroid group vs. 4/21 control at 8 
weeks, p<0.01. 
                       
Atchia et al 2011                    OARSI responder criteria: 7/19 in 
steroid group vs. 2/19 in control 
group at week 8, p=0.02. 
 statistically significant improvement compared to control (at an alpha level of 0.05).  no statistically significant improvement compared to control . Grey box – results not considered at this time point. * No statistical 
comparison between controls and steroid group reported † Data from subsequent Cme points excluded due to absence of control group at later time points. Abbreviations: NRS - Numerical rating scale, OARSI-Osteoarthritis 



















Hip IASI Control 
  
Odds Ratio 
Study Responders Total Responders Total Weight M-H, Fixed, 95% CI M-H, Fixed, 95% CI 




 Lambert et al 2007 22 31 4 21 52.30% 10.39 [2.73, 39.56] 
 




40 100% 7.80 [2.70, 22.48] 
  Total responders 29 6 
  
Heterogeneity: Chi2 =0.44, df=1 (p=0.51); I2=0% 
  Test for overall effect Z=3.80 (P=0.0001) Favours control Favours Hip IASI 

















FIGURE 4.  
 
 
 
 
 
